Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Embecta Corp.NASDAQ: EMBC

Gross Margin · Q2 FY2026 · quarter ended Mar 2026

Gross margin narrows to 56.4%

Gross margin was 56.4% in Q2 FY2026, down 5.9 pp from a year earlier. On a trailing-twelve-month basis it was 62.5%, down 1.2 pp year over year. Over 3 fiscal years it narrowed by 5.7 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.4%-10.8 pp QoQ
Last fiscal yearSep 2025
62.9%-2.0 pp YoY
LTMMar 2026
62.5%-1.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-5.9 pp——
1 year-2.0 pp——
3 years-5.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
62.9%
Year-over-year change
-2.0pp

Gross Margin vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 gross margin of 62.5% is the 6th highest of the 11 companies compared; the peer median is 53.9%.
  • Its year-over-year change of -1.2 pp is the 7th highest of 11, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -5.7 pp compares with a peer median of +0.9 pp.
EMBC Competitors Peer median
Gross Margin for EMBC and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
CDNACareDx, IncLTM Jun 202670.6% +3.7 pp+2.4 pp
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
SIGASIGA Technologies, Inc.LTM Mar 202665.4% -11.2 pp-22.0 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
EMBCEmbecta Corp.LTM Mar 202662.5% -1.2 pp-5.7 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202634.6% +5.5 pp-62.9 pp
EVHEvolent Health, Inc.LTM Mar 202614.1% -1.1 pp-8.3 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
PRMEPrime Medicine, Inc.LTM Mar 2026-1082.7% -1182.7 pp—
Peer median (excluding EMBC) 53.9%-0.6 pp+0.9 pp

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.